Kudrat M. Abdulkadyrov

Saint Petersburg, SPE, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial.

A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial.

Journal: British journal of haematology

Published: September 25, 2018

Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL.

Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL.

Journal: Leukemia & lymphoma

Published: November 11, 2016

Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.

Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.

Journal: Leukemia & lymphoma

Published: October 13, 2016

Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.

Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.

Journal: The Lancet. Haematology

Published: July 11, 2016

The combination treatment regimen of ruxolitinib with low-dose mercaptopurine or cytarabine in frail patients with blast-phase myelofibrosis.

The combination treatment regimen of ruxolitinib with low-dose mercaptopurine or cytarabine in frail patients with blast-phase myelofibrosis.

Journal: British journal of haematology

Published: June 14, 2016

Matrix metalloproteinase-9 in plasma of bone marrow aspirates of patients with acute myeloid leukemia and myelodysplastic syndrome

Matrix metalloproteinase-9 in plasma of bone marrow aspirates of patients with acute myeloid leukemia and myelodysplastic syndrome

Journal: Voprosy onkologii

Published: January 01, 2016

Role of molecular-genetic abnormalities in pathogenesis and risk stratification of multiple myeloma.

Role of molecular-genetic abnormalities in pathogenesis and risk stratification of multiple myeloma.

Journal: Voprosy onkologii

Published: January 01, 2016

Targeted therapy of polycytemia vera patients.

Targeted therapy of polycytemia vera patients.

Journal: Voprosy onkologii

Published: January 01, 2016

The specific features of diagnosis of mixed-phenotype acute leukemia: A combination of B-cell antigen expressions according to the results of flow cytometry and morphological markers of myeloid differentiation in blast cells: A clinical case

The specific features of diagnosis of mixed-phenotype acute leukemia: A combination of B-cell antigen expressions according to the results of flow cytometry and morphological markers of myeloid differentiation in blast cells: A clinical case

Journal: Terapevticheskii arkhiv

Published: September 23, 2015

Heterogeneity of acute myeloid leukemia with the translocation t(8;21)(q22;q22)

Heterogeneity of acute myeloid leukemia with the translocation t(8;21)(q22;q22)

Journal: Terapevticheskii arkhiv

Published: October 16, 2014

The specific features of the immunophenotype of blast cells in patients with de novo normal karyotype acute myeloid leukemia and FLT3-ITD mutation

The specific features of the immunophenotype of blast cells in patients with de novo normal karyotype acute myeloid leukemia and FLT3-ITD mutation

Journal: Terapevticheskii arkhiv

Published: April 30, 2014

Sotatercept in patients with osteolytic lesions of multiple myeloma.

Sotatercept in patients with osteolytic lesions of multiple myeloma.

Journal: British journal of haematology

Published: December 18, 2013

Showing 1-12 of 18

Last Updated: 09/26/2026